The phase-1 portion of the trial dosed healthy volunteers; the phase-1b portion of the trial dosed patients with presumed NAFLD, based on metabolic parameters.
The above is stated in ENTA's press release, but it might not be obvious from a cursory read.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.